The aim of the present study has been to assess the therapeutic efficacy of various
cytokines, singly or in combination, with and without chemotherapy (cyclophosphamide, Cy) …

Previous studies have demonstrated that progressive growth of the weakly immunogenic
MCA 106 murine sarcoma stimulated, in the draining lymph nodes, the production of tumor …

Monoclonal antibodies (mAB) with tumor specificity are able to enhance the immunological
specificity of interleukin 2 (IL-2)-activated lymphokine activated killer (LAK) cells. Antibodies …

We have earlier observed that 1, 3‐bis (2‐chloroethyl)‐l‐nitrosourea (BCNU), a
chemotherapeutic drug, cured 90–100% of mice bearing a syngeneic la− T‐cell lymphoma …

In contrast to CD8+ T cells, it has been difficult to establish consistently satisfactory
conditions for the bulk culture of antitumor CD4+ T cells in either mice or humans. This …

Recent studies have demonstrated efficacy of immunotherapies including interleukin-2 (IL-2)
in the treatment of malignancies in rodents and humans. High levels of IL-2 receptor-positive …

Lymph nodes (LN) draining progressively growing tumors contain tumor-sensitized but not
fully functional preeffector lymphocytes. These cells could acquire therapeutic efficacy and …

Progressive growth of immunogenic murine tumors elicits a tumor-specific but functionally
deficient T-cell immune response in the draining lymph nodes. These T cells, referred to as" …

The adoptive immunotherapy of cancer with sensitized T lymphocytes is well documented in
several animal models. These studies indicate the existence of precursor lymphocytes, in …

A major obstacle to the effective use of adoptive immunotherapeutic treatment of cancer is
the difficulty of obtaining tumor-reactive lymphocytes in either sufficient numbers or with …